Secondary dyslipidaemia after oral contraceptives;Sekundární dyslipidemie navozená souč asnými perorálními kontraceptivy

Vnitrni Lekarstvi

Volumn 55, Issue 10, 2009, Pages 929-933

  Soška, Vladimír ^a,b   Fiala, J ^c   Nebeska K ^c   Hruba D ^c  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Apolipoprotein A1; Apolipoprotein B; Dyslipidemia; Hormonal contraception

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ETONOGESTREL; GESTODENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DYSLIPIDEMIA; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CONTRACEPTIVES, ORAL, HORMONAL; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; TRIGLYCERIDES;

EID: 70449564481     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Crosignani PG for the ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006; 12: 483-497.
2. Dubey RK, Imthurn B, Zacharia LC et al. Hormone replacement therapy and cardiovascular disease: Where went wrong and where do we go from here? Hypertension 2004; 44: 789-795.
3. Ramakrishnan G, Rana A, Das C et al. Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue. Contraception 2007; 76: 297-305. (Pubitemid 47444291)
4. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-529.
5. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
6. Hulley SB, Grady D, Bush T et al. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopauzal women. JAMA 1998; 280: 605-613.
7. Derry PS. Update on hormones, menopause, and heart disease: evaluating professional responses to the women's health initiative. Health Care Women Int 2008; 29: 720-737.
8. Gompel A, Barlow D, Rozenberg S et al. Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study. Maturitas 2006; 55: 1-4.
9. Knopp RH, Broyles FE, Cheung M et al. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63: 1-11. (Pubitemid 32232176)
10. Tikkanen MJ. Role of plasma lipoproteins in the pathogenesis of atherosclerotic disease, with special reference to sex hormone effects. Am J Obstet Gynecol 1990; 163: 296-304.
11. Stampfer MJ, Willett WC, Colditz GA et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1998; 319: 1313-1317.
12. Svačina Š. Vedlejší účinky farmakoterapie na hladinu lipidů. Vnitř Lék 2007; 53: 408-411. (Pubitemid 46775193)
13. Marek J, Hána V, Kršek M. Jak ovlivňují kortikoidy, růstový hormon a estrogeny lipidy a aterosklerózu. Vnitř Lék 2007; 53: 386-390. (Pubitemid 46775188)
14. Wiegratz I, Jung-Hoffmann C, Gross W et al. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 1998; 58: 83-91. (Pubitemid 28449361)
15. Falsetti L, Pasinetti E. Effect of long term administration of an oral-contraceptive containing ethinylestradiol and cyproteron-acetate on lipid-metabolism in women with polycystic-ovary-syndrome. Acta Obstet Gynecol Scand 1995; 74: 56-60.
16. Gaspard U, Endrikat J, Desager JP et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69: 271-278.
17. Shawe J, Lawrenson R. Hormonal contraception in women with diabetes mellitus: special considerations. Treat Endocrinol 2003; 2: 321-330. (Pubitemid 37075637)
18. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71: 409-416. (Pubitemid 40725775)
19. Scharnagl H, Petersen G, Nauck M et al. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 mg or 30 mg) and levonorgestrel (100 mg or 150 mg) on lipoprotein metabolism. Contraception 2004; 69: 105-113.
20. Connelly PW, Stachenko S, MacLean DR et al. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Can J Cardiol 1999; 15: 419-427. (Pubitemid 29224873)
21. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.
22. Middleton J. Effect of analytical error on the assessment of cardiac risk by the high-sensitivity c-reactive protein and lipid screening model. Clin Chem 2002; 48: 1955-1962. (Pubitemid 35222754)
23. Austin M, Thompson GR, Hulley SB et al. Triglycerides are an independent risk factor for coronary heart disease - A debate. Atherosclerosis 1997; 134: 6.
24. Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033. (Pubitemid 34084825)
25. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in quiding therapy: report of the thirty-person/ten country panel. J Intern Med 2006; 259: 247-258.
26. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoA1, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006; 44: 1015-1021. (Pubitemid 44155874)
27. Walldius G, Jungner I, Aastveit AH et al. The apoB/apoA-1 ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 1355-1363. (Pubitemid 40057822)